

Hepatitis Testing/Diagnosis Market is growing at a CAGR of 5% from 2024 to 2030 by Exactitude Consultancy

The Exactitude Consultancy Hepatitis Testing/Diagnosis Market Report – Size, Trends, and Forecast 2024-2030

LUTON, BEDFORDSHIRE, UNITED KINGDOM, March 8, 2024 /EINPresswire.com/ -- ********Everything You Need to Know About [Hepatitis Testing/Diagnosis](#) everything is Here....!

The Comprehensive study on [Hepatitis Testing/Diagnosis Market](#)

includes historical data as well as share, size, and projection information for the major players, geographies, applications, and product categories for the years 2024 to 2030. The Market study includes comprehensive insights on the competitive environment, description, broad product portfolio of key players, SWOT analysis, and significant business strategy



The demand for hepatitis testing/diagnosis is increasing due to rising awareness, prevalence of hepatitis infections, and advancements in diagnostic technologies."

Exactitude Consultancy



implemented by rivals, revenue, Porters Five Forces Analysis, and sales projections. The report also features an impact analysis of the market dynamics, highlighting the factors currently driving and limiting market growth, and the impact they could have on the short, medium, and long-term outlook. The main goal of the paper is to further illustrate how the latest scenario, the economic slowdown, and war events affect the market for Hepatitis Testing/Diagnosis.

[Hepatitis Testing/Diagnosis Market](#)

includes historical data as well as share, size, and projection information for the major players, geographies, applications, and product categories for the years 2024 to 2030. The Market study includes comprehensive insights on the competitive environment, description, broad product portfolio of key players, SWOT analysis, and significant business strategy

□□□ □□□ □□□ □□□□□□□□ □□□□□□□□ □□ □□□ □□□□□□:

Hoffmann-La Roche Ltd, Abbott, Bio-Rad Laboratories Inc., Siemens, DiaSorin, QIAGEN, Danaher, bioMérieux SA, Grifols S.A., Ortho Clinical Diagnostics, FUJIREBIO Inc and Others.

□□□□□□ □□□□□□□□□□□□:

In 2021, Abbott received FDA Emergency Use Authorization (EUA) for the Alinity m Resp-4-Plex assay.

In 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics (US) which aimed at adding more products to Roche's molecular diagnostics portfolio and the global distribution of products offered by GenMark Diagnostics.

In 2021, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc. (South Korea). The partnership aims at collaborative development and the commercialization of infectious disease diagnostic

□□□□□ □□□ □□□□ □□ □□□ □ □□□□ □□□□□□□□ □□□□ □□ □□□ □□□□□□□□ :

<https://exactitudeconsultancy.com/reports/10753/hepatitis-testing-diagnosis-market/#request-a-sample>

(*If you have any special requirements, please let us know and we will provide you with the report as you wish.)

□□□□□□□□□□ □□□□□□□□/□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□:

□□□□□□ □□□□□□□□□□ □□□□□□□□/□□□□□□□□□□□□ □□□□□□ □□ □□□□□□□□ □□□□, □□□□-□□□□, (□□□□ □□□□□□□□)

Hepatitis B

Hepatitis C

Other Hepatitis

□□□□□□ □□□□□□□□□□ □□□□□□□□/□□□□□□□□□□□□ □□□□□□ □□ □□□□□□□□□□□□, □□□□-□□□□, (□□□□ □□□□□□□□)

Elisa

RDT

PCR

INAAT

□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□ □□□-□□□□□, □□□□□-□□□□□, (□□□□ □□□□□□□□)

Hospitals

Diagnostic Laboratories

Blood Banks

□□□□□ □□ □□□□□□□□□□, □□□□ □□□□□□□ □□□□□□ □□□ □□□□□□□□□□□□□ □□□ □□□□ □□□□□□□□□□ □□ □□□□□□□□:

North America dominates the global market, and this trend is expected to continue during the forecast period. The rising prevalence of hepatitis, as well as increased research and clinical trials for hepatitis testing in the United States, are the reason for this region's growth.

□□□□□□□□□□ □□□□□□ □□□□□□□□ □□ □□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□:

To study and analyze the global market size (value & volume) by company, key regions/countries, products and application, history data, and forecast to 2030.

To understand the structure of market by identifying its various sub segments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the growth trends, future prospects, and their contribution to the total market.

To project the value and volume of submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

□□□□□ □ □□□□□ □□ □□□□ □□ □□□□ □□□□□□□□ □□□□ □□□□□□□□ □□□□ □□□□□:

MARKET OVERVIEW

MARKET OVERVIEW: MARKET OVERVIEW AND MARKET OVERVIEW

Hepatitis is a major public health concern with a high prevalence rate worldwide, despite significant improvements in treatment options, vaccination coverage, and public awareness. Of all the hepatitis types, B and C are the most prevalent and contribute toward higher mortality rates. In 2019, an estimated 296 million and 58 million people were living with chronic HBV and chronic HCV infection, respectively. In underdeveloped countries, the prevalence of hepatitis is high as compared to developed countries

MARKET OVERVIEW: MARKET OVERVIEW AND MARKET OVERVIEW

In developing and low-resource countries, NAT is not mandatory due to the expensive nature of this test and the requirement of skilled personnel. In India, by 2016, only 58 out of a total of 2,550 (~2%) blood banks performed NAT for hepatitis diagnosis. In many developing countries such as India and China, ELISA is the only mandatory test, which acts as a major inhibitor for the adoption of NAT. In India, blood screening involves serological testing for hepatitis surface antigens; however, there are no mandates for using NAT. As a result, there is a lack of clarity about results among people undergoing hepatitis diagnostic tests, which acts as a restraint for market growth.

MARKET OVERVIEW: MARKET OVERVIEW AND MARKET OVERVIEW

The demand for immunoassay instruments and consumables is high in the biotechnology and biopharmaceutical industries. As a result, the growth of these industries is expected to support the growth of the market during the forecast period. In these industries, the growth of the end-user base has compelled many companies to launch new products and invest in developing advanced products. This is considered a positive indicator for market growth as immunoassays are applied at many stages— from product development and manufacturing to quality control—in production.

MARKET OVERVIEW: MARKET OVERVIEW AND MARKET OVERVIEW

Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory space also needs to be reconfigured to meet the requirements of conducting specific molecular diagnostic tests used for pathogen detection as a means of avoiding cross-contamination and ensuring efficient time management. This results in considerable cost escalation to maintain and

operate advanced molecular diagnostic instruments, particularly those capable of handling a single sample type. Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled and technically knowledgeable laboratory technicians to operate advanced hepatitis testing products has hindered their overall adoption, particularly in emerging markets.

□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□ □□□ □□□□□□□□□ □□□□□□□□:

□□□□□□ □□□□□□□□□□□□: Comprehensive information on the product portfolios of the top players in the Hepatitis Testing/Diagnosis

□□□□□□□□ □□□□□□□□□□□□/□□□□□□□□□□□□: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

□□□□□□□□□□□□ □□□□□□□□□□□□: In-depth assessment of the Hepatitis Testing/Diagnosis market strategies, geographic and business segments of the leading players in the market.

□□□□□□ □□□□□□□□□□□□: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

□□□□□□ □□□□□□□□□□□□□□□□□□: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Hepatitis Testing/Diagnosis

□□□□ □□ □□□ □□□ □□□ □□□□□□□□□□ □□□□□□□□□□□□ □□ □□□ □□□□□ □□□:

Which companies are expanding litanies of products with the aim to diversify product portfolio?

Which companies have drifted away from their core competencies and how have those impacted the strategic landscape of the Hepatitis Testing/Diagnosis market?

Which companies have expanded their horizons by engaging in long-term societal considerations?

Which firms have bucked the pandemic trend and what frameworks they adopted to stay resilient?

What are the marketing programs for some of the recent product launches?

□□□□□□□□ □□□□□□:

<https://exactitudeconsultancy.com/ko/reports/10753/hepatitis-testing-diagnosis-market/>

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.